Britain’s Haleon Rejects Potential Zantac Liabilities in U.S.

Haleon believes it is not liable for any claims that may arise from U.S. litigation over the heartburn drug Zantac, the London-listed company’s CEO Brian McNamara told Reuters on Tuesday. More than 2,000 legal cases related to Zantac have been …

from News Archives - Insurance Journal https://ift.tt/CWkAorR
via IFTTT